The type 2 diabetes therapy market will rapidly expand over our 2015-2025 study period, fueled by the disease’s increasing prevalence and a high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. However, these novel therapies predominantly represent later-to-market entrants of existing drug classes, or novel combination therapies of existing compounds. Among the drug classes expected to undergo the most rapid growth is the sodium glucose cotransporter (SGLT)-2 inhibitors, led by Boehringer Ingelheim/Eli Lilly’s empagliflozin (Jardiance), due to its demonstration of cardiovascular benefit in the EMPA-REG trial. The GLP-1 receptor agonists are also expected to demonstrate rapid growth due to their excellent HbA1c-lowering efficacy, potential for weight loss, and demonstrations of cardiovascular benefit for Novo Nordisk’s liraglutide (Victoza) and semaglutide. However, these and other emerging therapies will face major challenges, including reimbursement hurdles and an increasingly stringent regulatory environment. Nevertheless, as the patient population expands and significant needs remain, commercial opportunity will continue to grow.

 


Related Reports

Type 2 Diabetes - Landscape & Forecast - Disease Landscape & Forecast

View Details

Type 2 Diabetes | Disease Landscape and Forecast | G7 | 2020

The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in th...

View Details

Type 2 Diabetes - Epidemiology - Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key type 2 diabetes patient...

View Details

Type 2 Diabetes - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) Dashboard

Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes drugs and dominate the early lines of therapy, before disease progression requires insulin replacement. The emergence of...

View Details